LifeMD (NASDAQ:LFMD) Price Target Lowered to $9.00 at HC Wainwright

LifeMD (NASDAQ:LFMD) had its price objective cut by analysts at HC Wainwright from $13.00 to $9.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 126.87% from the company’s current price.

LFMD has been the subject of several other research reports. Wall Street Zen lowered shares of LifeMD from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Zacks Research upgraded LifeMD from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. Lake Street Capital dropped their price target on LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday. Mizuho reduced their price objective on LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, KeyCorp decreased their target price on LifeMD from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Wednesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, LifeMD has an average rating of “Moderate Buy” and a consensus target price of $9.43.

LifeMD Price Performance

Shares of NASDAQ:LFMD traded down $0.12 on Wednesday, hitting $3.97. The stock had a trading volume of 609,431 shares, compared to its average volume of 1,534,144. LifeMD has a twelve month low of $3.43 and a twelve month high of $15.84. The company has a debt-to-equity ratio of 9.21, a quick ratio of 0.72 and a current ratio of 0.77. The firm’s 50 day moving average price is $6.01 and its 200-day moving average price is $8.68. The company has a market capitalization of $188.10 million, a price-to-earnings ratio of -23.31 and a beta of 1.57.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Monday, November 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The company had revenue of $60.17 million for the quarter, compared to analyst estimates of $62.07 million. During the same period in the prior year, the business earned $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities research analysts predict that LifeMD will post -0.56 earnings per share for the current year.

Insider Transactions at LifeMD

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the company’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider owned 605,000 shares of the company’s stock, valued at approximately $3,581,600. This represents a 11.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 18.40% of the company’s stock.

Institutional Investors Weigh In On LifeMD

A number of institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC lifted its stake in shares of LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after acquiring an additional 1,351 shares during the period. Royce & Associates LP increased its position in LifeMD by 3.5% in the first quarter. Royce & Associates LP now owns 1,155,231 shares of the company’s stock worth $6,284,000 after purchasing an additional 39,240 shares during the period. GSA Capital Partners LLP raised its holdings in LifeMD by 39.9% during the 1st quarter. GSA Capital Partners LLP now owns 103,803 shares of the company’s stock worth $565,000 after purchasing an additional 29,582 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in LifeMD by 5.4% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 981,894 shares of the company’s stock worth $5,342,000 after purchasing an additional 50,600 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in LifeMD during the 1st quarter valued at about $143,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.